

Global PE firms line up for IndiaRF’s Synthimed Labs in $150-200 million deal
Mint first reported that IndiaRF has mandated Rothschild to help scout for buyers for the portfolio company that is seeking a valuation of about $1 billion.The stake sale underscores rising investor appetite for scaled API platforms with export-heavy books, especially as India’s pharma supply chain strengthens its position in regulated markets and private equity firms seek pre-IPO opportunities in defensible healthcare assets.“The exact amount of the ongoing fundraise is contingent to an acquisition that Synthimed is evaluating,” a third person said. “If the acquisition goes as planned, the round may potentially become larger with a primary capital infusion.
India RF, which is the majority shareholder in the company, may also consider other financing options including debt if the acquisition were to happen,” the person added.General Atlantic, IndiaRF, and Rothschild declined to comment while Synthimed, KKR, and CVC did not respond to Mint’s requests for a comment till the time of publishing.The development comes nearly three years after IndiaRF acquired the carved-out generic active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business of Ind-Swift Laboratories Ltd in March 2024 for a total consideration of ₹1,650 crore. The operations were subsequently housed under its portfolio company, SLPL.IndiaRF, a joint venture between the Piramal Group and Bain Capital, was founded about a decade ago and invested in the company through its first fund, which had a corpus of $629 million.
Read on livemint.com